A New Mouse Model to Explore Therapies for Preeclampsia by Ahmed, Abdulwahab et al.
A New Mouse Model to Explore Therapies for
Preeclampsia
Abdulwahab Ahmed
1., Jameel Singh
1., Ysodra Khan
1, Surya V. Seshan
2, Guillermina Girardi
1*
1Department of Biology, York College, City University of New York, New York, New York, United States of America, 2Department of Pathology, Weill Cornell Medical
College, New York, New York, United States of America
Abstract
Background: Pre-eclampsia, a pregnancy-specific multisystemic disorder is a leading cause of maternal and perinatal
mortality and morbidity. This syndrome has been known to medical science since ancient times. However, despite
considerable research, the cause/s of preeclampsia remain unclear, and there is no effective treatment. Development of an
animal model that recapitulates this complex pregnancy-related disorder may help to expand our understanding and may
hold great potential for the design and implementation of effective treatment.
Methodology/Principal Findings: Here we show that the CBA/J x DBA/2 mouse model of recurrent miscarriage is also a
model of immunologically-mediated preeclampsia (PE). DBA/J mated CBA/J females spontaneously develop many features
of human PE (primigravidity, albuminuria, endotheliosis, increased sensitivity to angiotensin II and increased plasma leptin
levels) that correlates with bad pregnancy outcomes. We previously reported that antagonism of vascular endothelial
growth factor (VEGF) signaling by soluble VEGF receptor 1 (sFlt-1) is involved in placental and fetal injury in CBA/J x DBA/2
mice. Using this animal model that recapitulates many of the features of preeclampsia in women, we found that pravastatin
restores angiogenic balance, ameliorates glomerular injury, diminishes hypersensitivity to angiotensin II and protects
pregnancies.
Conclusions/Significance: We described a new mouse model of PE, were the relevant key features of human preeclampsia
develop spontaneously. The CBA/J x DBA/2 model, that recapitulates this complex disorder, helped us identify pravastatin
as a candidate therapy to prevent preeclampsia and its related complications. We recognize that these studies were
conducted in mice and that clinical trials are needed to confirm its application to humans.
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Introduction
Preeclampsia (PE) is a pregnancy-specific, multisystemic disor-
der that occurs in about 1 in 12 of all live-birth pregnancies in the
United States, and it is a leading cause of maternal and fetal
mortality and morbidity [1,2]. More than 200,000 American
women per year develop PE (a number equal to the number of
women affected by breast cancer). It is the most common reasons
for a woman to die during pregnancy. This syndrome has been
known to medical science since ancient times. However, despite
considerable research, the cause/s of PE remain/s unclear, and
there is no effective treatment. Development of an animal model
that recapitulates this complex pregnancy-related disorder may
help to expand our understanding and may hold great potential
for the design and implementation of effective treatment.
DBA/2-mated female CBA/J mice (CBA/J 6 DBA/2) are a
well-studied model of immunologically mediated pregnancy loss
[3,4].We previously described the important contribution of
complement activation to adverse pregnancy outcomes in this
model [5]. In these abortion-prone matings, generation of the
anaphylotoxin C5a and increased tissue factor expression, causes
dysregulation of angiogenic factors and abnormal placental
development [5,6]. Diminished giant trophoblast cells, diminished
placental perfusion and bad pregnancy outcomes were observed in
CBA/J x DBA/2 mice [5,6]. Knowing that defective placentation
due to increased antiangiogenic soluble receptor for vascular
endothelial growth factor 1 (sFlt-1) can trigger PE in rodents and
women [7,8] and that inflammation has been implicated in the
pathogenesis of PE [9,10] led as to investigate if the CBA/J x
DBA/2 mating model constitutes a model of PE. Here we show
that the CBA/J x DBA/2 model of recurrent miscarriage is also a
model of PE that shares many features with human PE. With the
use of this unique mouse model that spontaneously develops the
pathological changes associated with PE, we examined the
beneficial effects of pravastatin in preventing the onset of the
characteristic features of PE. Pravastatin restored angiogenic
balance and prevented the onset of the key preeclamptic
symptoms in CBA/J x DBA/2 mice.
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Bad pregnancy outcomes in first pregnancy
We previously reported that embryos derived from mating
CBA/J females with DBA/2 males showed an increased frequency
of resorption when compared to control matings BALB/c-mated
CBA/J female mice and that surviving fetuses from CBA/J x
DBA/2 matings showed consistent and significant intrauterine
growth restriction (IUGR) [5]. The expressivity of the phenotype
(fetal loss and IUGR) in CBA/J x DBA/2 matings was constant.
100% DBA/2-mated CBA/J mice presented increased fetal
resorption frequency and smaller fetuses.
PE is twice as common in primigravid women as in women
having second or later pregnancies, suggesting an immune cause
[11]. Despite the increased fetal resorption rate observed in first
mating of CBA/J females with DBA/2 males, increased fetal death
and growth restriction was not observed in the second and third
pregnancies (Fig 1A). In addition, IUGR was not observed in the
2
nd and 3
rd pregnancies in CBA/J x DBA/2 mice. Fetal weights in
second and third pregnancies (356636 mg and 370645mg
respectively) were not different from those observed in control
mating pairs CBA/J x BALB/c (348641 mg) (n=140-160
fetuses/experimental group). Fetal weight in CBA/J x BALB/c
matings did not change in relation to the number pregnancies
(data not shown) (n=120 fetuses/group). A group of mice was
studied until birth and litter sizes were recorded (Fig 1B). In
CBA/J x DBA/2 mice the litter sizes in the first pregnancy were
smaller compared to the 2
nd and 3
rd pregnancy. Litter sizes in 2
nd
and 3
rd pregnancy were not different from values observed in
control CBA/J x BALB/c matings (Fig 1B). 6 to 8 mice were
studied in each experimental group.
Increased albuminuria and glomerular endotheliosis in
CBA/J x DBA/2 mice
The presence of proteinuria is used to confirm the diagnosis of
PE [12]. In CBA/J x DBA/2 mice, a time-course increase in urine
albumin to creatinine ratio (ACR), that reaches statistic signifi-
cance at day 10 of pregnancy, was observed (Fig 1C). On day 15
Figure 1. Preeclamptic features in CBA/J x DBA/2 matings. Increased fetal resorption frequency (A) and decreased litter size (B)) were
observed only in first pregnancies in DBA/2 mated CBA/J mice. Normal pregnancies (not different from control matings CBA/J x BALB/c) were
observed in second (2
nd P) and third (3
rd P) pregnancies with the same male. Data are mean values plus or minus SD. (C) In CBA/J x DBA/2 mice, a
time-course increase in urine albumin to creatinine ratio (ACR), that reaches statistic significance at day 10 of pregnancy, was observed (*p,0.05 vs
CBA/J x DBA/2). Albuminuria was not observed in control matings CBA/J x BALB/c mice. N=6-8 mice/experimental group (Di) Transmission electron
micrographs of glomeruli from DBA/J mated CBA/J mice (original magnification 10,000x) show swelling of glomerular endothelial cells and loss of
fenestrations. Numerous red blood cells trapped between swollen endothelial cells were observed occluding the glomerular capillaries. No signs of
endothelial injury, well preserved fenestrations and widely patent glomerular capillary lumina are observed in kidneys from CBA/J x BALB/c mice
(control group) (Ei). (Dii) Kidney perfusion studies reveal diminished blood perfusion (the fluorescent tracer did not accumulate in the glomerular
capillaries) in glomeruli from CBA/J x DBA/2 mice with abnormal pregnancies compared to control CBA/J x BALB/c matings (Eii). (Diii) Increased fibrin
staining in glomeruli from CBA/J x DBA/2 mice when compared to CBA/J x BALB/c mice (Eiii). (Div and Eiv) Jones methenamine silver staining.
Diffusely and irregularly thickened glomerular basement membranes were observed in some glomeruli in CBA/J x DBA/2 mice (20%) (Fig 1Div)
compared to BALB/c mated CBA/2 females (Fig 1Eiv). Kidneys from 5-6 mice were studies in each experimental group.
doi:10.1371/journal.pone.0013663.g001
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than that measured in control mice (Figure 2A). In CBA/J x
BALB/c mice a very slight increase in ACR was observed through
pregnancy (Fig 1C). Proteinuria was not observed in second and
third pregnancies in CBA/J x DBA/2 mice (data not shown).
Endotheliosis, an inflammation of the glomerular endothelium,
is a frequent renal lesion observed in women with PE [12].
Electron microscopic analysis (EM) was performed to identify
endothelial injury in CBA/J x DBA/2 mice. EM examination of
renal glomerular capillaries in CBA/J xDBA/2 mice showed
endothelial swelling with reduction of endothelial fenestrations
(Fig 1Di). Swollen glomerular endothelial cells occupied a wide
area of the capillaries lumina and clumping of red cells occluded
the capillary lumina in 30% of the glomeruli in CBA/J x DBA/2
mice. In the control CBA/J x BALB/c mating, glomeruli
presented open capillary lumens and intact endothelial cells
(Fig 1Ei). Women with PE have a decrease in glomerular filtration
and renal blood flow [13]. Decreased renal blood flow was
observed in some kidneys from CBA/J x DBA/2 mice (30%) at
day 15 of pregnancy (Fig 1Dii) when compared to CBA/J x
BALB/c mice (Fig 1Eii). Increased fibrin deposition, another
characteristic of glomerular endotheliosis, was also observed in
kidneys from CBA/J x DBA/2 matings (Fig 1Diii) compared to
CBA/J x BALB/c mice (Fig 1Eiii). Jones methenamine silver
staining showed diffusely and irregularly thickened glomerular
basement membranes in some glomeruli in CBA/J x DBA/2 mice
(20%) (Fig 1Div) compared to BALB/c mated CBA/2 females
(Fig 1Eiv). These renal lesions characteristic of human PE were
only observed in the first pregnancy of DBA/2 mated CBA/J mice
(data not shown).
Blood pressure in DBA/2 mated CBA/J females
Hypertension is the most common diagnostic signs in PE and
results from high peripheral resistance. However, no difference in
mean arterial blood pressure (MAP) was observed in CBA/J x
DBA/2 mice when compared to control matings (Fig 2A). MAP
was slightly higher in the DBA/2 mated CBA/J females from day
8 to day 15 of pregnancy but did not reach statistical significance
when compared to control matings (Fig 2A). In women, blood
pressure decreases during a normal pregnancy because of the
decrease in peripheral vascular resistance. This pattern was also
observed in control pregnant mice (CBA/J x BALB/c), where the
mean change in MAP from mating day decreased between days 8
and 15 in BALB/c mated CBA/J mice. Although not statistically
Figure 2. MAP and contractile response to angiotensin II in CBA/J x DBA/2 mice. (A) No significant increase in MAP was observed in CBA/J x
DBA/2 compared to CBA/J x BALB/c control matings. Data were expressed as change in MAP from mating day. CBA/J x DBA/2 mice showed an
increase response to an acute a bolus injection of AngII compared to CBA/J x BALB/c mice (*p,0.01). The response to Ang II was expressed as the
mean change in MAP from basal values before Ang II injection. (B) Aortic rings from CBA/J x DBA/2 and CBA/J x BALB/c contracted in response to Ang
II (* p,0.05). Aortic rings from CBA/J x DBA/2 mice showed increased reduction of the inner diameter in response to Ang II (# different from CBA/J x
BALB/c. P,0.05). N=8–10 mice/experimental group. (C) Staring at day 11 of pregnancy, plasma leptin levels were increased in CBA/J x DBA/2 mice
when compared to control CBA/J x BALB/c matings (* p,0.01). This increase was maintained until delivery. Leptin levels in CBA/J x DBA/2 and control
matings drop to pre-pregnancy values after parturition. N=6–8 mice/experimental group.
doi:10.1371/journal.pone.0013663.g002
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DBA/2 mice (Fig 2A).
Increased sensitivity to Ang II in CBA/J x DBA/2 mice
An increased sensitivity of the arteries to vasoconstrictor agents
like angiotensin II (Ang II) has been described in PE. Thus, we
investigated if increased hypersensitivity to Ang II was present in
the CBA/J x DBA/2 model. In response to a bolus injection of
Ang II, MAP increased by 3265 mmHg in CBA/J x DBA/2 mice
and 1664 mm Hg in CBA/J x BALB/c control matings (Fig 2A).
The increase in MAP in response to Ang II was statistically greater
in CBA/J x DBA/2 mice compared to CBA/J x BALB/c mice
(P,0.001). This pronounced and sustained pressor hypersensitiv-
ity to Ang II was observed in CBA/J x DBA/2 mice from days 12
to 18 of pregnancy. In addition, aortic rings from CBA/J x DBA/
2 mice showed increased contractile response to Ang II
(100 mmol/L) when compared to aortic rings from control
CBA/J x BALB/c matings. Aortic rings from CBA/J x DBA/2
mice showed a 4566% reduction in diameter compared to
2264% in control matings (Fig 2B). Increased sensitivity to AngII
was only observed in first CBA/J x DBA/2 pregnancies. Second
and third pregnancies show a response to Ang II not different from
control matings CBA/J x BALB/c (18%64 diminution in
diameter).
Effect of wheel running on blood pressure
In the previous set of experiments MAP was monitored in
CBA/J x DBA/2 and CBA/J x BALB/c at rest. In this set of
experiments, day 12 pregnant mice were subjected to wheel
running for a period of 5 minutes. MAP was recorded before and
after wheel running. Wheel running induced a MAP increased
only in preeclamptic CBA/J x DBA mice (1563 mmHg) when
compared to control matings (261 mmHg). CBA/J x DBA/mice
did not show hypertension during pregnancy. However, stimulus
like Ang II or exercise triggered hypertension in these mice.
Leptin levels in CBA/J x DBA/2 mice
To substantiate the characterization of our mouse model of PE
we measured plasma leptin levels. Plasma leptin levels are
significantly elevated in pregnant women with PE and the increase
in plasma leptin levels is correlated with the severity of
preeclampsia [14]. Plasma leptin levels increased through
pregnancy in both CBA/J x DBA/2 and control matings but in
CBA/JxDBA/2 mice a bigger increase was observed at day 12 of
pregnancy (Fig 2C). This increase in plasma leptin levels observed
in CBA/J x DBA/2 matings was maintained until delivery. After
delivery the leptin values dropped to non pregnant levels (NP) in
CBA/J x DBA/2 and control CBA/J x BALB/c matings (Fig 2C).
Pravastatin prevents preeclamptic features in CBA/J x
DBA/2 mice
Knowing that pravastatin, by diminishing tissue factor levels,
prevented miscarriages and growth restriction in the CBA/J x
DBA/2 model [6], we sought to investigate whether pravastatin
can prevent the onset of key features of PE in CBA/J x DBA/2
mice. In accord with our previous findings, we found that
pravastatin attenuated glomerular injury in CBA/J x DBA/2
mice. Figure 3A shows that ACR levels in CBA/J x DBA/2 mice
were reduced by pravastatin. Accordingly, EM analysis of kidneys
from these mice revealed normal configuration of glomerulus
(Fig 3Bi). The capillary lumina were not occluded and there were
no signs of endothelial injury. The endothelium was thin and the
fenestrations were abundant and well preserved (Fig 3Bi). Fibrin
deposition and decreased glomerular blood flow were not observed
in the CBA/J x DBA/2 mice that received pravastatin. (Fig 3Bii
and 3Biii). Similar to the EM studies, Jones methenamine silver
staining showed no abnormalities in the glomerular basement
membranes (Fig 3Biv).
CBA/J x DBA/2 mice treated with pravastatin did not show
hypertension in response to Ang II or wheel running when
compared to untreated CBA/J x DBA/2 mice (response to Ang II:
1263v s3 2 65 mmHg, p,0.01; wheel running: 262v s1 5 6
3 mmHg, p,0.05). Aortic rings from CBA/J xDBA/2 mice that
were treated with pravastatin showed a contractile response to Ang
II not different from control matings (Fig 3C).
Pravastatin increased free plasma VEGF levels
We previously demonstrated a severe angiogenic imbalance in
DBA/2 mated CBA/J mice, characterized by increased plasma
sFlt-1 levels and low free VEGF levels [5]. CBA/J x DBA/2 mice
that received pravastatin showed free plasma VEGF levels
comparable to control matings (CBA/J x BALB/c) (Fig 4A).
Previous results from our laboratory showed that pravastatin
prevents sFlt-1 release from macrophages and thus rescue
pregnancies [6]. Here we investigated if pravastatin can increase
VEGF levels by stimulating VEGF release from trophoblasts.
Figure 4B illustrates the effects of pravastatin (5, 10 and 20 mg/
ml) on VEGF release by mouse trophoblasts SM-9. The basal
trophoblast VEGF secretion was increased by pravastatin in a
dose-dependent-manner. Pravastatin increased SM9-1 trophoblast
proliferation in a dose-dependent manner (Fig 4C). Pravastatin
restores VEGF levels in the CBA/J x DBA/2 model by a dual
mechanism: inhibition of sFlt-1 release from macrophages [6] and
stimulation of VEGF release from trophoblasts.
VEGF121 reduced glomerular injury and abrogated
albuminuria in CBA/J x DBA/2 mice
To confirm that pravastatinprevents PE in the CBA/J x DBA/
2 mice by restoring the levels of VEGF, we treated DBA/J mated
CBA/2 females with VEGF121. It has been reported that
delivery of recombinant VEGF121 attenuates hypertension and
prevents kidney damage in rat models of PE characterized by
chronic elevations of sFlt-1 [15,16]. Chronic administration of
VEGF121 restoredcirculating VEGFlevelsto the levels observed
in CBA/J x BALB/c mice with normal pregnancies (data not
shown). Glomerular injury observed in CBA/J x DBA/2 mice
was not observed in mice that received VEGF121 treatment
(Fig 4Di).Inaddition, VEGF121 chronic treatmentalsorestored
glomerular blood flow and diminished fibrin deposition in
glomerular capillaries in CBA/J x DBA/2 mice (Fig 4Dii and
iii). The protective effects of VEGF121 on glomerular endothe-
lium were also reflected in the absenceof albuminuria.On day 15
of pregnancy, ACR levels in CBA/J x DBA/2 mice treated with
VEGF121 were not different from values in control matings
(Fig 4E). Increased hypersensitivity to Ang II vasoconstrictor
effects was not observed in CBA/J x DBA/2 mice that received
VEGF121 compared to CBA/J x DBA/2 untreated mice (MAP
1063v s3 2 65 mmHg, p,0.01). Chronic infusion of VEGF also
prevented IUGR in CBA/J x DBA/2 mice. Fetuses from CBA/J
x DBA/2 mice treated with VEGF121 had similar body weights
to fetuses from control CBA/J x BALB/c matings (data not
shown).
Aortic rings from CBA/J xDBA/2 mice treated with VEGF121
did not show increased contractile response to Ang II when
compared to untreated CBA/J x DBA/2 mice (aorta inner
diameter (mm): 0.7160.02 vs 0.3760.03, p,0.01) The contractile
Therapy for Preeclampsia
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from control matings (0.6960.02 mm).
Discussion
The preeclampsia/eclampsia syndrome has been recognized
since ancient times. PE is a serious complication of pregnancy that
increases maternal and perinatal morbidity and mortality and it
still affects approximately 10% of pregnancies. Despite consider-
able research effort, very little is understood about its etiology and
pathophysiology, which are complex and multifactorial. For many
years it was arguable if an animal model can be of use in
preeclampsia studies, as it was a human disease that was not
observed spontaneously in other species. In this study we report
several novel findings. Foremost we report a new mouse model
were the relevant key features of preeclampsia appear spontane-
ously without genetic [17,18] or surgical manipulation [19] or the
administration of any compound to induce the condition [7,20].
The CBA/J x DBA/2 model, that recapitulates the key
preeclamptic symptoms, helped us identify mediators of PE and
identify possible therapies. The fact that CBA/J x DBA/2 mice
develop preeclampsia-like disease with all the accepted patholog-
ical changes (hypersensitivity to Ang II, proteinuria and renal
glomeruloendotheliosis suggests that this mouse model is indeed an
appropriate model of human PE. Using this model, we found that
pravastatin restores the angiogenic balance by increasing VEGF
release from trophoblasts and thus ameliorates preeclamptic
features and rescues pregnancies in this model.
PE is documented to occur primarily in first pregnancies and
rarely in subsequent pregnancies. Therefore, the concept of
primigravidity is the epidemiological cornerstone of this disease
[21]. In our mice studies we found that only first pregnancies in
CBA/J females mated with DBA/2 males were complicated by PE
while subsequent pregnancies were not associated with the disease.
These studies share the concept of primigravidity with human
preeclamptic pregnancies. It was also proposed that PE is a disease
ofnewcouples, especiallyaftera shortperiodofsexualcohabitation,
creating and alternative primipaternity model [11,21], our studies
also follow the primipaternity model as second and third
pregnancies with the same male resulted in normal pregnancies.
PE has been termed the ‘‘disease of theories’’, reflecting the
confusion that surrounds the causes and pathophysiology of PE
[22]. Because PE only occurs during pregnancy and its symptoms
resolve after delivery, factors produced by the placenta are thought
to initiate widespread inflammation, thrombosis and vasoconstric-
tion [8,23]. Maternal hypertension is one of the key features of PE
in women. Mice show similar gestation stage-dependent changes
in maternal blood pressure to human. During a normal pregnancy
blood pressure actually falls during gestation in humans and mice
as well [24,25]. Wong and colleagues reported that arterial blood
pressure was transiently reduced in midgestation (9–13 days) in
control pregnant mice [25]. A similar pattern was observed in
control CBA/J x BALB/c mice with normal pregnancies. Despite
the similarities in blood pressure during gestation in mice and
humans, we were unable to demonstrate blood pressure increase
in the CBA/J x DBA/2 mice with abnormal pregnancies. We only
Figure 3. Pravastatin prevents glomerular injury and hypersensitivity to angiotensin II in CBA/J x DBA/2 mice. (A) Increased ACR levels
were observed in CBA/J x DBA/2 mice along pregnancy (* p,0.01). Treatment with pravastatin abrogated albuminuria in CBA/J x DBA/2 mice (B)
CBA/J x DBA/2 mice treated with pravastatin showed no signs of renal endothelial damage. (Bi) EM studies (original magnification 10,000 x) showed
well preserved endothelial cells and open capillaries lumen in CBA/J x DBA/2 mice treated with pravastatin. (Bii) Increased fibrin deposition was not
observed in glomerular capillaries from DBA/2 mated CBA/J mice that received pravastatin. (Biii) Pravastatin restored renal blood flow in CBA/J x DBA/
2 mice. (Biv) Jones methenamine silver staining shows no signs of endotheliosis in CBA/J x DBA/2 mice treated with pravastatin. (C) Aortic rings from
CBA/J x DBA/2 mice treated with pravastatin did not show increased contractile response in response to Ang II when compared to untreated CBA/J x
DBA/2 mice (*p,0.05). N=5–8 mice/experimental group.
doi:10.1371/journal.pone.0013663.g003
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statistical significance. The absence of hypertension in this model
can be due to the method used to monitor BP. However, the fact
that the non invasive tail cuff technology was validated by
comparison to simultaneous radiotelemetry blood pressure
measurements [26] makes this unlikely. We also need to consider
that we did not monitor blood pressure continuously; MAP was
recorded for a short period of time each day. Another possible
reason to explain the absence of hypertension in CBA/J x DBA/2
mice when compared to women is the different gestation time.
Gestation in mice lasts 20 days, with formation of the beating heart
and vascularized placenta completed by day 10. Therefore, the
events of later development that take the last 8 months of gestation
in humans occur in only the last 9 days in mice. Thus, there is a
rather short time for hypertension to develop in mice. As such, it is
possible that hypertension observed in human disease may not
occur in mice due to the short time periods. Because there are
descriptions of clinical presentations with pregnancy-induced
features of PE but without hypertension in women [27,28], the
absence of hypertension does not reduce the usefulness of the
CBA/J x DBA/2 model because it is clearly a pregnancy induced
disorder with strong preeclamptic features.
Even in the absence of hypertension, we demonstrated an
increased vascular susceptibility to vasoconstriction. CBA/J x
DBA/2 mice showed increased sensitivity to Ang II and exercise
when compared to control CBA/J x BALB/c matings. The
increased response to Ang II observed in CBA/J x DBA/2 mice
can be also caused by decreased formation of vasodilators such as
nitric oxide (NO). We previously demonstrated a marked
diminution in plasma NO levels during pregnancy in DBA/J
mated CBA/J females when compared to control matings [6].
These data are consistent with the observations in woman, as
enhanced vascular sensitivity to an angiotensin infusion can
identify women who are at increased risk for the development of
PE [29,30]. An heterodimer of the G-protein2coupled angioten-
sin II type I and bradykinin B2 receptors might be involved in the
molecular mechanism of this phenomenon [31]. Zhou and
collaborators have shown that women with PE possess autoanti-
bodies, termed AT(1)-AAs, that bind and activate the angiotensin
II receptor type 1a [32]. In addition, they showed that key features
of PE appeared in pregnant mice after injection with purified
AT(1) AAs from women with PE [32].
In PE, there is a reduced invasion of trophoblasts and an
incomplete transformation of the maternal spiral arteries [9,10]
causing the release of factor(s) from the defective placenta into the
maternal circulation [23]. These factors are believed to induce the
endothelial dysfunction underlying the main characteristics of
preeclampsia [7]. sFlt-1, the soluble receptor for VEGF, seems to
Figure 4. Pravastatin restores angiogenic balance in CBA/J x DBA/2 mice. (A) Pravastatin restored free plasma VEGF levels in CBA/J x DBA/2
mice (*p,0.05). (B) SM9-1 trophoblast cells incubated with pravastatin showed increase VEGF release in a dose dependent manner (*p,0.05). Values
are expressed as percentage of control values.(C) Pravastatin (5- 10-20 mg/ml) increased cell proliferation in SM9-1 trophoblasts in a dose-dependent
manner. (D) CBA/J x DBA/2 mice treated with VEGF 121 showed no signs of endotheliosis. (Di) electron microscopy studies show well preserved
glomerular endothelial cells in CBA/J x DBA/2 mice treated with VEGF121.original magnification 10,000 x (Dii) Adequate blood perfusion comparable
to CBA/J x BALB/c control matings was observed in CBA/J x DBA/2 mice treated with VEGF121. (Diii) Increased fibrin deposition was not observed in
glomerular capillaries from DBA/2 mated CBA/J mice that received VEGF121. (E) Pravastatin ameliorated ACR in CBA/J x DBA/2 mice at day 15 of
pregnancy (* p,0.01). N=6–8 mice/experimental group.
doi:10.1371/journal.pone.0013663.g004
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PE [7,8]. We previously showed the crucial role of sFlt-1 and
angiogenic imbalance in the CBA/J x DBA/2 model [5,6].
Endotheliosis is a frequent renal lesion observed in patients with
PE. Morphometric analysis of the kidneys of CBA/J x DBA/2
mice revealed significant ultrastructural differences when com-
pared to control mating, including swelling of the glomerular
endothelial cells, fibrin deposition and occlusion of capillary
lumens. These renal features are consistent with endotheliosis.
Moreover, reduced renal blood flow, also present in women with
PE, was also observed in the CBA/J x DBA/2 mouse model of PE.
The presence of proteinuria confirms the diagnosis of PE and
the amount of protein excreted in the urine is related to the
severity of the disease in women. In CBA/J x DBA/2 mice we
observed a time course increase of albumin to creatinine ratio,
reaching maximum values at day 15 of gestation. Proteinuria in
preeclamptic women usually develops at the end of the second
trimester, beginning of the third trimester. Considering that the
length of pregnancy in mice is 19-21 days, proteinuria in CBA/J x
DBA/2 mice was observed at the same time period than in
humans.
During pregnancy, leptin concentrations in the maternal circula-
tion are elevated in both humans and rodents but decrease to pre-
pregnancy levels at birth, suggesting a role for leptin in the
maintenance of pregnancy [14]. Synthesis of leptin by the human
placenta is established but whether the murine placenta synthesizes
leptin remains controversial. We observed increased serum leptin
levels in preeclamptic CBA/J x DBA/2 mice. However we could not
identify the source of the increased leptin levels. Mouse trophoblasts
incubates with leptin (data not shown) showed normal proliferation.
The fact that leptin did not affect mouse trophoblasts growth in cell
culture suggests that the increased levels of leptin observed in our PE
model is rather a compensatory mechanism to maintain trophoblasts
growth than the cause of trophoblast defective invasiveness.
A concept that preeclampsia may represent and exaggerated
hyperinflammatory state that leads to destruction of trophoblasts
was described more than 10 years ago by Redman and
collaborators [10]. Haeger and colleagues suggest that the
endothelial dysfunction in PE is caused by intravascular
inflammatory reactions involving intravascular leukocytes as well
as the clotting and complement systems [33]. Our observations are
in agreement with these studies as we described an important role
for inflammation (in particular complement activation) and
thrombosis in the bad pregnancy outcomes in the CBA/J x
DBA/2 model [5,6]. We demonstrated that complement activa-
tion induces tissue factor expression on macrophages stimulating
sFlt-1 release and causing placental angiogenesis failure and
abnormal pregnancies.
Knowing that statins have anti-inflammatory effects [34] and
protected pregnancies in the CBA/J x DBA/2 matings [6], we
sought to investigate if statins can prevent the onset of PE-specific
features in CBA/J x DBA/2 mice. Treatment with pravastatin
prevented the appearance of the key features of PE in CBA/J x
DBA/2 mice. Glomerular endothelial lesions and proteinuria were
not observed in CBA/J x DBA/2 mice that were treated with
pravastatin. That treatment with pravastatin during early stages of
pregnancy (from day 4 to 12) prevents the onset of the maternal
vascular disease of PE observed later in pregnancy suggests that
poor placental development may be the underlying cause of PE.
We previously described diminished giant trophoblasts cells in
CBA/J x DBA/2 mice which suggests a deficient trophoblast
invasion during placentation [5].
CBA/J x DBA/2 mice treated with pravastatin did not show
increased susceptibility to Ang II pressor effects. In addition the
contractile response of aortic rings to Ang II in CBA/J x DBA/2
mice treated with pravastatin was not different from control
matings. This is in agreement with studies suggesting that statins
lower blood pressure in hypertensive patients [35].
In vitro studies emphasize the beneficial effects of pravastatin in
the treatment of preeclampsia. Increased VEGF release was
observed in mouse trophoblasts incubated with increasing doses of
pravastatin. We previously demonstrated that pravastatin inhib-
ited the release of sFlt-1 from macrophages [6]. Thus pravastatin
may prevent PE-specific features by restoring angiogenesis and
placental development through two different mechanisms: de-
creasing sFlt-1 levels and increasing VEGF levels. Other authors
also demonstrated that statins decreased the release of sFlt-1 from
endothelial cells and normal –term placental villous explants [36].
In conclusion, we described a new mouse model of PE, where
the relevant key features of human preeclampsia appear
spontaneously. The CBA/J x DBA/2 model, that recapitulates
this complex disorder, helped us identify pravastatin as a candidate
therapy to prevent preeclampsia and its related complications.
Clinical trials are needed to confirm its application to humans.
Materials and Methods
Mice matings and treatment protocol
Inbred CBA/J (H-2k), DBA/2 (H-2d), and BALB/c (H-2d)
mice from The Jackson Laboratory (Bar Harbor, ME) were used
in all experiments. Eight- to 10-week-old virgin female CBA/J
mice were mated with 8- to 14-week-old BALB/c or DBA/2
males. Females were inspected daily for vaginal plugs; sighting a
vaginal plug was designated as day 0 of pregnancy.
A group of CBA/J x DBA/2 and CBA/J x BALB/c mice were
treated with pravastatin (20 ug/kg, sc) daily from day 4 to 12 of
pregnancy. Another group of mice received vascular endothelial
growth factor (VEGF) 121, the most soluble of VEGF isoforms,
subcutaneously through a mini osmotic pump (Alzet, Cupertino,
CA) (20 mg/kg/day) from day 4 to day 10 of pregnancy.
Minipumps filled with VEGF121 in sterile PBS were implanted
on day 4 of pregnancy under isofluorane anesthesia. Blood and
urine samples were collected at predetermined intervals (from day
0 until delivery). Plasma leptin levels were measured by ELISA
(Cayman Chemical Company, Ann Arbor, MI). VEGF plasma
levels were determined by ELISA (R&D Systems Inc, Minneapo-
lis, MN).
On day 15 a group of mice were sacrificed and aortic rings were
isolated. Kidneys were also harvested to investigate the presence of
endotheliosis. The frequency of fetal resorption and fetal weight
were also determined on day 15 as previously described [5,6].
To study the effect of primiparity on the development of
preeclampsia, a group of CBA/J x DBA/2 mice completed their
first or second pregnancy and were mated again with the same
male. Litter sizes were recorded immediately after birth. A group
of these mice were sacrificed on day 15 and fetal resorption
frequency was calculated as previously described [5,6]. Proce-
dures that involved mice were approved by the York College –
CUNY- Committee on Animal Use in Research and Education
and were conducted in strict accordance with guidelines for the
care and use of laboratory research animals promulgated by the
NIH.
Blood Pressure Measurements
Blood pressure was measured in the tail artery in pregnant
CBA/J x BALB/c mice and CBA/J xDBA/2 mice with and
without pravastatin or VEGF121 treatment at different times
along pregnancy until postpartum. Measurements were performed
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(CODA System, Kent Scientific Corporation, Torrington, CT,
USA) [26]. The CODA system utilizes volume-pressure recording
technology to detect changes in tail volume that correspond to
systolic and diastolic pressures and calculates mean arterial
pressure (MAP) during each measurement cycle. Our protocol
consisted of 8 acclimation cycles and 8 measurement cycles daily.
Unanesthetized mice were placed in plastic holders. Mouse body
temperatures was monitored closely and maintained between
34uC and 36uC using infrared heating. Readings differing by more
than 10 mmHg were repeated after a rest period of 15-20 minutes.
A group of CBA/J x BALB/c and CBA/J x DBA/2 received a
bolus injection of AngII (100 mL, 3 mmol/kg) via the retro-orbital
vein. MAP was measured before and 10 minutes after Ang II
injection. A group of mice was subjected to MAP monitoring
before and after wheel running for 5 min.
Assesment of Albumin/creatinine ratio (ACR)
Albumin-to-creatinine ratio (ACR) in random urine specimens
(accepted alternative to 24-hour urine collections) was used to
monitor kidney function. Urinary albumin was determined by
ELISA (Albuwell M (Exocell, Philadelphia, PA). Creatinine in
urine was quantified with the Creatinine Companion kit (Exocell,
Philadelphia, PA), based upon the Jaffe’ reaction of alkaline picrate
with creatinine.
Immunohistochemistry
Kidneys from every experimental group were acquired at day 15
of gestation and frozen quickly in O.C.T. compound (Sakura
Finetek, CA). 10 mm-thick sections were cut and endogenous
peroxidase activity was quenched with Peroxo-block (Invitrogen
Corporation, Camarillo, CA). Sections were incubated with normal
rabbit serum to block nonspecific binding (Cappel, Aurora, OH),
then incubated with rabbit anti-mouse fibrin ((Dako North America
Inc.,Carpinteria, CA), followed by incubation with specific
secondary IgG antibodies conjugated with HRP (Sigma Chemical,
St Louis, MO). Bound IgG-HRP was detected with diaminobenzi-
dine. Sections were counterstained with hematoxylin.
Renal blood perfusion was examined by injecting pregnant
females with 100 mL of 25 mg/mL FITC-labeled dextran (MW
2000000; Sigma-Aldrich, St Louis, MO) via the retro-orbital vein,
at day 15 of pregnancy. After 15 minutes, the mice were killed and
the kidneys removed and flash frozen. Serial frozen sections were
examined and photographed under a fluorescence microscope
(Nikon 50i) attached to a DigiSight Color digital camera system
(Nikon DSRi1).
A group of kidneys were fixed in 2% paraformaldehye/2%
glutaraldehyde in 0.1 M phosphate buffer for electron microscopy
(EM). Kidney sections were evaluated for the presence of
endotheliosis (loss of fenestrations, endothelial swelling and
detachment of endothelial cells from the glomerular basement
membrane). Jones methenamine silver staining was also performed
in kidneys to identify glomerular lesions.
Trophoblast cells culture
SM9-1 trophoblast cells, derived from a gestational day 9 Swiss
-Webster mouse placenta [37], were cultured in RPMI-1640
supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 2-
mercaptoethanol (2-ME), penicillin/streptomycin and 10% FBS.
Adherent SM9-1 trophoblasts cells were incubated with different
concentrations of pravastatin (Sigma Chemicals, St Louis, MO) (5,
10 and 20 mg/ml). After 24 hours, cell proliferation was evaluated
by light microscopy and VEGF levels were measured in the
supernatants by ELISA (R&D Systems Inc, Minneapolis, MN).
Isolation of aortic rings
CBA/J x BALB/c and CBA/J x DBA/2 mice untreated or
treated with pravastatin were euthanized by cervical dislocation on
day 15 of pregnancy. The abdominal-thoracic aorta was then
excised, placed in cold PBS, and cleaned of adhering connective
and adipose tissue. Aorta from each mouse was divided into 4
rings of 2-mm length. Each of the aortic rings was incubated in
2 mL DMEM medium containing either vehicle (dH2O) or Ang II
(100 nmol/L) for 60 min. The inner diameters were calculated by
measuring luminal diameter through the transverse section of the
thin-vessel ring by using a calibrated micrometer eyepiece.
Luminal diameters were measured at three points separated by
equal angles and averaged. 5 mice were studied in each
experimental group.
Statistical analysis
Data are expressed as mean plus or minus standard deviation.
After confirming that the data were normally distributed
(Kolomogorov-Smirnov test of normalcy), statistical analyses were
conducted using Student t test to compare differences in means.
Associations were considered to be statistically significant if the
value of P was less than 0.05. Data were processed using
SigmaStat, version 3.1 (Systat, Point Richmond, CA), statistical
program forWindows.
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